Novel Therapies for Type 2 Diabetes Mellitus / 대한소아내분비학회지
Journal of Korean Society of Pediatric Endocrinology
;
: 11-18, 2009.
Article
in Korean
| WPRIM
| ID: wpr-198308
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and betacell dysfunction. The role of new hormones and systems in maintaining blood glucose homeostasis has recently been recognized. This recognition has led to the development of several novel classes of medications, including the incretin mimetic agents (glucagon like polypeptide-1 analogs and dipeptidyl peptidase IV inhibitors), the amylin analog and the endocannabinoid-1 receptor blocker. This review looks at these new agents in terms of their mode of action, pharmacokinetics and use in clinical practice. The new agents offer treatment options in select adult patients now, however, the efficacy and the safety has to be evaluated thoroughly by long term studies before the application to pediatric patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Glucose
/
Insulin Resistance
/
Dipeptidyl Peptidase 4
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptides
/
Dipeptidyl-Peptidase IV Inhibitors
/
Incretins
/
Islet Amyloid Polypeptide
/
Homeostasis
Limits:
Adult
/
Humans
Language:
Korean
Journal:
Journal of Korean Society of Pediatric Endocrinology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS